Match Document Document Title
US20140105886 ASSOCIATION OF BIOMARKERS WITH PATIENT OUTCOME  
Glioblastoma multiforme (GBM) is an aggressive form of brain cancer. Biomarkers for GBM that provide prognostic and predictive information are useful because they provide the physician valuable...
US20150079116 DIAGNOSTIC TOOLS FOR RESPONSE TO 6-THIOPURINE THERAPY  
NK cell licensing predisposes patients to chronic inflammatory disease. Methods and kits to diagnose and treat chronic inflammatory disease based on genetic haplotype and cytokine profile are...
US20150250770 LKB1 AS PREDICTIVE MARKER OF EVEROLIMUS EFFICACY IN BREAST CANCER  
Method for identifying a breast cancer likely to respond to treatment with everolimus comprising the following steps: Measuring the level of expression of the LKB 1 gene in a breast tumour sample...
US20130018069 SUSTAINED RELEASE DELIVERY SYSTEMS FOR THE PREVENTION AND TREATMENT OF HEAD AND NECK CANCERS  
The present invention discloses a method of treating a head and neck cancer or preventing the development of pre-malignant lesions to this cancer, by administering locally to the oral cavity, a...
US20110224245 Treatment Of Neurological Disorders Using Huperzine  
Methods and compositions containing huperzine for direct delivery to central nervous system (CNS) tissue are used to alleviate pain and for the prevention and/or treatment of seizures and...
US20140056999 TREATMENT OF ACUTE EXACERBATION OF ASTHMA AND REDUCTION OF LIKELIHOOD OF HOSPITALIZATION OF PATIENTS SUFFERING THEREFROM  
The invention provides a method of improving one or more clinical outcomes of an individual experiencing an acute respiratory attack. The acute respiratory attack may include acute reversible...
US20110117213 TREATMENT OF ACUTE EXACERBATION OF ASTHMA AND REDUCTION OF LIKELIHOOD OF HOSPITALIZATION OF PATIENTS SUFFERING THEREFROM  
The invention provides a method of improving one or more clinical outcomes of an individual experiencing an acute respiratory attack. The acute respiratory attack may include acute reversible...
US20140336215 Rhinitis Treatment Regimens  
A method of treating rhinitis and rhinorrhea includes taking a daytime oral dosage unit containing a non-sedating antihistamine for treating rhinitis and an anticholinergic agent having limited...
US20110086081 COATING SYSTEM AND METHOD FOR DRUG ELUTION MANAGEMENT  
The teachings are directed to a medical device having a drug-retaining coating that at least substantially delays the initial elution of a drug for a time effective at forming a functional...
US20130022661 BIO-REMODABLE BONE AUGMENTATION DEVICE AND METHOD  
A bio-remodable augmentation device including an implantable member configured for maintaining space in a bone defect. The implantable member is formed from a bio-remodable composite having...
US20110150775 GENOMIC APPROACHES TO FETAL TREATMENT AND DIAGNOSIS  
The present invention provides systems for developing and/or testing therapies for prenatal diseases and conditions including Down Syndrome. The present invention also provides diagnostic methods...
US20150004154 REGIMEN FOR SUPPRESSING ORGAN REJECTION  
The present invention relates to a method of suppressing organ rejection in a patient receiving an organ transplant by initiating oral treatment with a once-daily extended release tacrolimus...
US20110104228 SELF-ELIMINATING COATINGS  
The invention features the use of a matrix consisting of low molecular weight components for use as a self-eliminating coating for implantable medical devices. The matrix coatings can be used to...
US20110045050 NANOEMULSION FORMULATIONS FOR DIRECT DELIVERY  
A nanoemulsion and corresponding methods of making and using systems of single or blended high HLB value surfactant(s) for the emulsification of single or blended oils and vitamin E components in...
US20130017257 DRY POWDER FORMULATION CONTAINING TIOTROPIUM FOR INHALATION  
The present invention is related to a dry powder formulation containing tiotropium to be administered via inhalation, the use of said formulation in the treatment of respiratory diseases...
US20120136046 METHOD OF TREATING AGE RELATED DISORDERS  
The present invention relates to the use of fujimycin for the treatment of a disorder related to the chronological and/or replicative life-span of a cell, and to methods for increasing the...
US20120076770 Modulation of autophagy and and serotonin for treatment of multiple myeloma related diseases  
THE INVENTION RELATES TO compounds, proteins and methods of treatment therewith. Aspects of embodiments of the invention further relates to compounds and methods of treatment for bone, bone...
US20140080834 INHIBITION OF ADAPTOR ASSOCIATED KINASE 1 FOR THE TREATMENT OF PAIN  
This invention is directed to the treatment of pain by inhibiting adaptor associated kinase 1 (AAK1). Numerous AAK1 inhibitors are disclosed.
US20130213398 DRY POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES  
The present invention is directed toward respirable dry particles for delivery of divalent metal cation salts and/or monovalent cation salts to the respiratory tract and methods for treating a...
US20130231346 METHODS OF TREATING CANCER  
Methods for treating a human with cancer comprise administering a therapeutically effective amount of at least one MEK inhibitor and at least one mTOR inhibitor to said patient, wherein said...
US20150133378 METHOD FOR PREDICTING RISK OF EXPOSURE TO INTERSTITIAL FIBROSIS AND TUBULAR ATROPHY WITH CLUSTERIN  
A method for identifying a kidney transplant recipient at an increased risk of developing interstitial fibrosis or tubular atrophy which comprises obtaining a post-transplant urine sample from the...
US20100322894 Combination Therapies for Treating Type 1 Diabetes  
In accordance with the subject invention, combination therapies can be used to modulate a patient's immune response in order to prevent, delay and/or reverse type 1 diabetes.
US20110028418 USE OF GABBA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EXCESSIVE SLEEPINESS AND DISORDERS ASSOCIATED WITH EXCESSIVE SLEEPINESS  
GABAA receptor mediated hypersomnia can be treated by administering a GABAA receptor antagonist (e.g., flumazenil; clarithromycin; picrotoxin; bicuculline; cicutoxin; and oenanthotoxin). In some...
US20140024642 OPHTHALMIC FORMULATION AND METHOD FOR AMELIORATING PRESBYOPIA  
An ophthalmic formulation having an effective amount of a parasympathomimetic agent comprising pilocarpine, or a pharmaceutically acceptable salt thereof, and one or more α1 adrenergic agonists or...
US20120015035 Implantable Delivery Vehicle for Ocular Delivery of Muscarinic Antagonists  
The present invention provides compositions and methods for treating ocular disorders such as myopia.
US20120059027 TACROLIMUS INJECTION PREPARATION  
A tacrolimus injection preparation comprising tacrolimus, polyoxyethylene castor oil (35), and non-aqueous solvent is disclosed. Preferably the weight ratio of polyoxyethylene castor oil (35) to...
US20140194461 RAPAMYCIN FORMULATIONS AND METHODS OF THEIR USE  
Described herein are liquid rapamycin formulations. Described herein are methods of treating or preventing diseases or conditions, such as choroidal neovascularization, wet AMD and dry AMD, and...
US20110165256 COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPLASIA  
In accordance with the present invention, there are provided methods for treating hyperplasia in a subject in need thereof. In another aspect of the invention, there are provided methods for...
US20140080783 PHARMACEUTICAL COMBINATIONS FOR TREATMENT OF SPECIFIC CANCERS  
The present invention relates to the field of oncology and provides compositions and methods for treating specific cancers, including non small cell lung cancer, breast cancer, thyroid cancer,...
US20120071435 PHARMACEUTICAL COMBINATIONS COMPRISING FOR THE TREATMENT OF SPECIFIC CANCERS  
The present invention relates to the field of oncology and provides compositions and methods for treating specific cancers, including non small cell lung cancer, breast cancer, thyroid cancer,...
US20110311605 Coating Designs For The Tailored Release Of Dual Drugs From Polymeric Coatings  
Provided herein are coating designs for the tailored release of two therapeutic agents from polymer coatings and methods of making and using the same.
US20110251677 Coating Designs For The Tailored Release Of Dual Drugs From Polymeric Coatings  
Provided herein are coating designs for the tailored release of two therapeutic agents from polymer coatings and methods of making and using the same.
US20140378500 METHODS FOR PREDICTING TUMOR REPONSE TO TARGETED THERAPIES  
A method for identifying cancer patients that are likely to be responders or non-responders to a signal transduction pathway inhibitor is described.
US20140303091 OCULAR FORMULATIONS OF NORKETOTIFEN  
Ophthalmic compositions containing norketotifen and methods of making the same and the use thereof are disclosed. The methods also comprise administering to the eyes of a mammal in need thereof...
US20130261148 PROTECTED ANTIMICROBIAL COMPOUNDS FOR HIGH TEMPERATURE APPLICATIONS  
Provided are protected antimicrobial compounds which are useful for controlling microorganisms in aqueous or water-containing systems, such as oil or gas field fluids, at elevated temperature. The...
US20140370072 PROHEALING PIEZOELECTRIC COATINGS  
Provided herein is a prohealing piezoelectric coating and the method of making and using the same.
US20120329759 FORMULATIONS AND METHODS FOR VASCULAR PERMEABILITY-RELATED DISEASES OR CONDITIONS  
Described herein are formulations and methods for treating, inhibiting, preventing, delaying onset, or causing regression of a disease or condition relating to vascular permeability.
US20110224128 METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY  
The invention features methods, compositions, and kits useful for the treatment of muscular dystrophy, e.g., Duchenne muscular dystrophy, in a patient.
US20110311629 NON-ADHESIVE ELASTIC GELATIN MATRICES  
The present invention is a substantially non-adhesive elastic gelatin matrix. The matrix is both non-adhesive to wounds, tissues and organs and is also elastic such that it is flexible. The matrix...
US20110097402 NON-ADHESIVE ELASTIC GELATIN MATRICES  
The present invention is a substantially non-adhesive elastic gelatin matrix. The matrix is both non-adhesive to wounds, tissues and organs and is also elastic such that it is flexible. The matrix...
US20140356407 BIODEGRADABLE SUPPORTING DEVICE  
A biodegradable in vivo supporting device is disclosed. The in vivo supporting device comprises a biodegradable metal scaffold and a biodegradable polymer coating covering at least a portion of...
US20130236498 BIODEGRADABLE SUPPORTING DEVICE  
A biodegradable in vivo supporting device is disclosed. The in vivo supporting device comprises a biodegradable metal scaffold and a biodegradable polymer coating covering at least a portion of...
US20140303201 CANCER THERAPY  
The subject invention provides for cancer therapy.
US20090060922 Acetamide Stereoisomer  
The compound of formula (I) is a water-stable, long acting β2-selective adrenoceptor agonist useful as a bronchodilator in the treatment of bronchoconstriction associated with reversible...
US20110301105 COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS  
We have discovered that p63 inhibition results in increased cellular proliferation. We have also performed a screen for agents capable of increasing cellular proliferation, (e.g., of stem cells...
US20110118298 COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF CANCER  
Described herein are compositions, kits, and methods for determining whether subjects having cancer(s) are likely to respond to treatment with an HSP90 inhibitor, as a single agent or in...
US20140357660 GENE EXPRESSION SIGNATURES OF NEOPLASM RESPONSIVENESS TO THERAPY  
Gene signatures for determining whether a neoplasm (such as a multiple myeloma neoplasm) is sensitive to mTORi/HDACi combination therapy and/or for determining the prognosis of a neoplasm in a...
US20140011834 STABLE FORMULATIONS, AND METHODS OF THEIR PREPARATION AND USE  
Described herein are formulations comprising therapeutic agents, including but not limited to formulations comprising rapamycin, pharmaceutical formulations, unit dose forms, kits, methods of...
US20110118297 Tivozanib and Temsirolimus in Combination  
A method of treating a tumor in a human patient is disclosed. The method comprises co-administering to the patient: (a) a dose of 1.5 mg tivozanib per day; and (b) a dose of 25 mg temsirolimus per...
US20130225631 TOPICAL RAPAMYCIN FOR TREATMENT OF FACIAL ANGIOFIBROMAS IN TUBEROUS SCLEROSIS  
The present disclosure provides for a method and a topical composition to treat facial angiofibromas in Tuberous Sclerosis by applying from about 0.25% to about 2% rapamycin to a small body...